NuCana Q2 Loss Narrows to £3.1M; Cash Runway Extended into 2029
NCNA sits 22% above its 52-week low of $1.21 on light trading volume (0.3× avg).
Summary
NuCana reported a much smaller Q2 loss and extended its cash runway into 2029, while confirming its Phase 2 melanoma study remains on track for final data in 2026.
Key Events · Earnings and Guidance · NCNA
-
Q2 Loss Narrows to £3.1M
Net loss fell to £3.1 million from £24.1 million in Q2 2025, mainly due to lower share-based payments and no repeat of the £12.6 million non-cash warrant revaluation loss.
-
Cash Runway Extended into 2029
Cash and cash equivalents of £19.5 million at June 30, 2026 are expected to fund operations into 2029, reducing near-term capital raise risk.
-
Phase 2 Melanoma Study Fully Recruited
Recruitment is complete in the NuTide:701 expansion study of NUC-7738 plus pembrolizumab in PD-1 inhibitor-resistant melanoma; final data remains on track for 2026.
-
ATM Sales Continue Post-Quarter
After June 30, 2026, the company sold 275,712 ADSs under its ATM program for gross proceeds of £0.3 million, bringing total ADSs outstanding to 4,583,567.
Analysis · NCNA · Life Sciences
NuCana's second-quarter loss narrowed sharply to £3.1 million from £24.1 million a year earlier, driven by lower share-based compensation and the absence of a £12.6 million non-cash warrant revaluation loss. Cash of £19.5 million is now expected to fund operations into 2029, removing near-term financing risk. The company also completed recruitment in its Phase 2 melanoma study, with final data still on track for 2026.
At the time of this filing, NCNA was trading at $1.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6M. The 52-week trading range was $1.21 to $7.22. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.